New arrivalYou can now listen to Fox News articles.
The recurrence of symptoms that occurred in some patients treated with “COVID-19 Rebound”, Paxrovid, may actually be caused by inadequate drug exposure. Clinical infections..
Recently, the Centers for Disease Control and Prevention (CDC) has issued health recommendations to individuals regarding the “COVID-19 Rebound”. In this case, in some patients, the symptoms of COVID infection recurred after treatment with Paxrovid. According to researchers, Paxlovid is currently the leading oral drug used to prevent severe cases of COVID-19 in high-risk patients.
“Paxrovid’s goal is to prevent serious illness and death, and so far, people who get sick again don’t have to be hospitalized, so it’s still doing its job,” said the person responsible for the infectious disease. Senior author Davy M. Smith, Ph.D. of Medicine, UC San Diego Medical College Global Public Health and UC San Diego Health Infectious Diseases Specialist said in a news release.
Researchers at the University of California, San Diego School of Medicine evaluated one patient who suffered a “Covid-19 rebound” after being treated with Paxrovid. According to the authors of the study, they found that the recurrence of COVID symptoms in patients after taking Paxrovid was not due to the development of resistance to the drug or weakened immunity to the coronavirus, but the amount of the drug was inadequate. , Found to be due to exposure to the drug.
Drugs for COVID: The United States Moves to Make Antiviral Drugs More Accessible
“Our main concern was that the coronavirus may have developed resistance to Paxrovid, so we were reassured that it wasn’t,” said the University of California, San Diego. Aaron F. Carlin, MD, the lead author and assistant professor of the School of Medicine. Said in the release.
Researchers isolated the SARS-CoV-2 BA.2 virus from COVID-19 rebound patients and tested for drug resistance. After treatment with the drug, Smith’s team found that the virus was still sensitive to Paxrovid and did not show mutations that would reduce the effectiveness of the drug.
Researchers also took a sample of the patient’s plasma and found that the patient’s antibodies were still effective in preventing the virus from invading and infecting new cells. They said this suggests that immune system disorders may be ruled out as a factor in individual recurrence.
Researchers in California concluded that COVID-19 rebound after the course of Paxrovid treatment was likely due to inadequate drug exposure. The authors further obtain sufficient drug for infected cells to stop all viral replication, either because the drug metabolizes too quickly in some patients or because the drug requires long-term administration. I explained that it means not doing it.
Florida GOV.Ron DeSantis says the White House is lying about the COVID vaccine policy
In the release, Carlin said he hopes doctors can test to see if patients need a longer course of treatment with Paxrovid or if they need a combination of medications.
In the release, the author stated that Paxlovid users should be aware of the risk of symptom rebound and follow precautions such as wearing a mask or quarantining if the symptom recurs.
Click here to get the Fox News app
Researchers also noted that further research is needed to determine how common this type of rebound is and which patients are the most vulnerable.
“We just need to understand why rebounds occur in some patients and not in others. Further research is needed to adjust treatment plans as needed,” Smith said in a release. Stated.